Shanghai Junshi Biosciences Co (HKSE:01877) 3-Year Book Growth Rate : 0.10% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co 3-Year Book Growth Rate?

Shanghai Junshi Biosciences Co's Book Value per Share for the quarter that ended in Mar. 2024 was HK$7.57.

During the past 3 years, the average Book Value per Share Growth Rate was 0.10% per year. During the past 5 years, the average Book Value per Share Growth Rate was 16.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 8 years, the highest 3-Year average Book Value per Share Growth Rate of Shanghai Junshi Biosciences Co was 65.60% per year. The lowest was 0.10% per year. And the median was 36.50% per year.

Competitive Comparison of Shanghai Junshi Biosciences Co's 3-Year Book Growth Rate

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Junshi Biosciences Co's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's 3-Year Book Growth Rate falls into.

Shanghai Junshi Biosciences Co 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Shanghai Junshi Biosciences Co (HKSE:01877) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Shanghai Junshi Biosciences Co 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

8SJ:Germany 688180:China

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines